Emerging Infectious Diseases (Mar 2022)

Sensitivity of Mycobacterium leprae to Telacebec

  • Ramanuj Lahiri,
  • Linda B. Adams,
  • Sangeeta Susan Thomas,
  • Kevin Pethe

DOI
https://doi.org/10.3201/eid2803.210394
Journal volume & issue
Vol. 28, no. 3
pp. 749 – 751

Abstract

Read online

The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis. The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.

Keywords